Advertisement

Liquid Biopsy for Investigation of Cancer DNA in Esophageal Squamous Cell Carcinoma

  • Robert A. SmithEmail author
  • Alfred K. Lam
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2129)

Abstract

Early detection of cancer and the monitoring of cancer recurrence in treated patients are significant challenges in esophageal squamous cell carcinoma (ESCC). Liquid biopsy is the identification of tumor biomarkers from minimally invasive samples of biological fluids, including urine, blood, stool, saliva, or cerebrospinal fluid. Liquid biopsy offers a potential solution to the problems of detection and surveillance as DNA shed from cancer cells as cell-free DNA or in exosomes can be detected in body fluids. By detecting these DNAs, we can identify the presence of cancer-associated mutations for basic detection, as well as to obtain information on the recurrence and evolution of disease following initial treatment. These sources of information have the potential to significantly improve the management of patients with ESCC. In this chapter, we detail a method for the isolation of cell-free DNA from blood plasma and DNA associated with exosomes in blood from patients with esophageal squamous cell carcinomas.

Key words

Liquid biopsy Cell-free DNA Exosome-associated DNA Cancer surveillance Cancer detection Cancer management Mutations 

References

  1. 1.
    Castro C, Peleteiro B, Lunet N (2018) Modifiable factors and esophageal cancer: a systematic review of published meta-analyses. J Gastroenterol 53:37–51CrossRefGoogle Scholar
  2. 2.
    Luo H, Li H, Hu Z, Wu H, Liu C, Li Y, Zhang X, Lin P, Hou Q, Ding G, Wang Y, Li S, Wei D, Qiu F, Li Y, Wu S (2016) Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 471:596–602CrossRefGoogle Scholar
  3. 3.
    Li X, Ye M, Zhang W, Tan D, Jaffrezic-Renault N, Yang X, Guo Z (2019) Liquid biopsy of circulating tumor DNA and biosensor applications. Biosens Bioelectron 126:596–607CrossRefGoogle Scholar
  4. 4.
    Lianidou E, Pantel K (2019) Liquid biopsies. Genes Chromosomes Cancer 58:219–232CrossRefGoogle Scholar
  5. 5.
    Hsieh CC, Hsu HS, Chang SC, Chen YJ (2016) Circulating cell-free DNA levels could predict oncological outcomes of patients undergoing esophagectomy for esophageal squamous cell carcinoma. Int J Mol Sci 17:E2131CrossRefGoogle Scholar
  6. 6.
    Ueda M, Iguchi T, Masuda T, Nakahara Y, Hirata H, Uchi R, Niida A, Momose K, Sakimura S, Chiba K, Eguchi H, Ito S, Sugimachi K, Yamasaki M, Suzuki Y, Miyano S, Doki Y, Mori M, Mimori K (2016) Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence. Oncotarget 7:62280–62291CrossRefGoogle Scholar
  7. 7.
    Ruivo CF, Adem B, Silva M, Melo SA (2017) The biology of cancer exosomes: insights and new perspectives. Cancer Res 77:6480–6488CrossRefGoogle Scholar
  8. 8.
    Elazezy M, Joosse SA (2018) Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J 16:370–378CrossRefGoogle Scholar
  9. 9.
    Corcoran RB, Chabner BA (2018) Application of cell-free DNA analysis to cancer treatment. N Engl J Med 379:1754–1765CrossRefGoogle Scholar
  10. 10.
    Fettke H, Kwan EM, Azad AA (2019) Cell-free DNA in cancer: current insights. Cell Oncol (Dordr) 42:13–28CrossRefGoogle Scholar
  11. 11.
    Alidousty C, Brandes D, Heydt C, Wagener S, Wittersheim M, Schäfer SC, Holz B, Merkelbach-Bruse S, Büttner R, Fassunke J, Schultheis AM (2017) Comparison of blood collection tubes from three different manufacturers for the collection of cell-free DNA for liquid biopsy mutation testing. J Mol Diagn 19:801–804CrossRefGoogle Scholar
  12. 12.
    Eisenberger CF, Knoefel WT, Peiper M, Merkert P, Yekebas EF, Scheunemann P, Steffani K, Stoecklein NH, Hosch SB, Izbicki JR (2003) Squamous cell carcinoma of the esophagus can be detected by microsatellite analysis in tumor and serum. Clin Cancer Res 9:4178–4183PubMedGoogle Scholar
  13. 13.
    Ikoma D, Ichikawa D, Ueda Y, Tani N, Tomita H, Sai S, Kikuchi S, Fujiwara H, Otsuji E, Yamagishi H (2007) Circulating tumor cells and aberrant methylation as tumor markers in patients with esophageal cancer. Anticancer Res 27:535–539PubMedGoogle Scholar
  14. 14.
    Ling ZQ, Zhao Q, Zhou SL, Mao WM (2012) MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 38:326–332CrossRefGoogle Scholar
  15. 15.
    Das M, Sharma SK, Sekhon GS, Saikia BJ, Mahanta J, Phukan RK (2014) Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India. Asian Pac J Cancer Prev 15:9955–9960CrossRefGoogle Scholar
  16. 16.
    Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H, Fujiwara H, Kikuchi S, Okamoto K, Ochiai T, Otsuji E (2007) Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res 27:2737–2741PubMedGoogle Scholar
  17. 17.
    Xu Y, Xie Z, Lu H (2018) Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment. J Cancer Res Ther 14:103–105CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  1. 1.Genomics Research Centre, Institute of Health and Biomedical InnovationQueensland University of TechnologyKelvin GroveAustralia
  2. 2.Cancer Molecular Pathology, School of MedicineGriffith UniversityGold CoastAustralia

Personalised recommendations